Download PDF
Pneumologie 2021; 75(01): 69-71
DOI: 10.1055/a-1251-6424
Leserbrief

Greulich T, Fähndrich S, Clarenbach C et al. Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement. Pneumologie 2020; 74: 436-442, doi:10.1055/a-1143-8186

M. Unnewehr
1   Innere Medizin V – Pneumologie, Infektiologie, Schlafmedizin, Allergologie St. Barbara-Klinik Hamm
,
A. Schlesinger
2   Lungenklinik Köln-Nord, Betriebsteil St. Marien Hospital Köln
,
S. Stieglitz
3   Medizinische Klinik I – Pneumologie, Allergologie, Schlaf- und Intensivmedizin Petrus Krankenhaus Wuppertal
,
D. Köhler
4   Ehem. Krankenhaus Kloster Grafschaft, Schmallenberg
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Das Expertenstatement [1] weist in einigen Punkten Unklarheiten und Widersprüche auf, insbesondere die Augmentationstherapie des Alpha-1-Antitrypsin-Mangels betreffend.



Publication History

Article published online:
18 January 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Greulich T, Fähndrich S, Clarenbach C. et al. Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement [Alpha-1 Antitrypsin Deficiency (AATD) – D-A-CH-Expert Statement]. Pneumologie 2020; 74: 436-442
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Stockley RA. et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136
    CrossrefPubMedGoogle Scholar
  • 3 Köhler D. Alpha-1-Antitrypsin-Mangel: Ist die Substitution ein Mythos?. Dtsch Arztebl 2017; 114: 24 https://www.aerzteblatt.de/pdf.asp?id=195382
    CrossrefPubMedGoogle Scholar
  • 4 Chapman KR, Burdon JG, Piitulainen E. et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360-368
    CrossrefPubMedGoogle Scholar
  • 5 Celli BR, Cote CG, Marin JM. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.  N Engl J Med 2004; 350: 1005-1012
    CrossrefPubMedGoogle Scholar
  • 6 Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; 07: CD007851
    PubMedGoogle Scholar
  • 7 Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2016; 9: CD007851
    PubMedGoogle Scholar
  • 8 Kohnlein T. et al. Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency. Pneumologie 2014; 68: 492-495
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Sandhaus RA, Turino G, Brantly ML. et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016; 3: 668-682
    PubMedGoogle Scholar
  • 10 Miravitlles M. et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J 2017; 50: pii: 1700610
    CrossrefPubMedGoogle Scholar
  • 11 NICE guideline: Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2018: 30 www.nice.org.uk/guidance/ng115
    PubMedGoogle Scholar